Organization named in the records

Celgene

Named in 22 passages across 6 documents.

Mentions of Celgene in the public Epstein records, with citations.

--}}

Being named in these documents is not an accusation or evidence of wrongdoing. This page reflects only what the public records literally contain, with citations to the original sources.

Where Celgene appears

22 total
…:156,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"In financial filings, Celgene said these price hikes were a main reason the drug’s net sales increased in 2017 by about $1.2 billion over the previous y...
Text 001 House Oversight 028413 TEXT-001-HOUSE_OVERSIGHT_028413.txt p.1 View source release ↗
…d Otezla, a psoriasis drug, badly missed sales expectations.","type":"text"},{"additions":[{"URL":"https://ir.celgene.com/press-releases/press-release-details/2017/Celgene-Provides-Update-on-GED-0301-mongersen-Inflammatory-Bowel-Disease-Pro...
Text 001 House Oversight 028413 TEXT-001-HOUSE_OVERSIGHT_028413.txt p.1 View source release ↗
…textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"“This is really concerning conduct and Celgene is by far the worst offender,” Michael Carrier, a professor at Rutgers Law School who studies patent law, said of Celgene’...
Text 001 House Oversight 028413 TEXT-001-HOUSE_OVERSIGHT_028413.txt p.1 View source release ↗
default-body","role":"body","text":"Yet, according to three lawsuits filed by generic drug companies, Celgene did just that.","type":"text"},{"identifier":"_anf-body-44","inlineTextStyles":[{"range":{"length":315,"start":0},"textStyle":"_an...
Text 001 House Oversight 028413 TEXT-001-HOUSE_OVERSIGHT_028413.txt p.1 View source release ↗
…_anf-ts-1"}],"layout":"default-body","role":"body","text":"To protect the profits from Revlimid and Thalomid, Celgene mounted an aggressive campaign to extend its monopoly.","type":"text"},{"identifier":"_anf-body-39","inlineTextStyles":[{"...
Text 001 House Oversight 028413 TEXT-001-HOUSE_OVERSIGHT_028413.txt p.1 View source release ↗
… treatments for multiple myeloma, a disease that affects more than 30,000 patients a year, was a windfall for Celgene.","type":"text"},{"additions":[{"URL":"https://media.celgene.com/content/uploads/revlimid-long-form.pdf","range":{"length"...
Text 001 House Oversight 028413 TEXT-001-HOUSE_OVERSIGHT_028413.txt p.1 View source release ↗
…ever, Mr. Hugin and other top executives repeatedly referred to Thalomid — and later Revlimid — as the key to Celgene’s financial future, even though it would not get formal approval to market the drugs to treat certain cancers until 2005 a...
Text 001 House Oversight 028413 TEXT-001-HOUSE_OVERSIGHT_028413.txt p.1 View source release ↗
…319,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"The F.D.A. reprimanded Celgene multiple times in those early years, telling the company that it had not adequately warned about thalidomide’s risks in it...
Text 001 House Oversight 028413 TEXT-001-HOUSE_OVERSIGHT_028413.txt p.1 View source release ↗
…experience in oncology, according to financial filings, and just months after Thalomid arrived on the market, Celgene announced that it would pursue F.D.A. approval for multiple myeloma.","type":"text"},{"components":[{"caption":"Mr. Hugin...
Text 001 House Oversight 028413 TEXT-001-HOUSE_OVERSIGHT_028413.txt p.1 View source release ↗
…}],"layout":"default-body","role":"body","text":"At the time, the company’s financial situation was perilous. Celgene had 200 employees and was getting by on less than six weeks of cash when Mr. Hugin joined, according to his campaign biogr...
Text 001 House Oversight 028413 TEXT-001-HOUSE_OVERSIGHT_028413.txt p.1 View source release ↗
0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"In 1998, Celgene’s application was approved to treat erythema nodosum leprosum, a complication of leprosy, which is extremely rare in the United States. In 2007, Cel...
Text 001 House Oversight 028413 TEXT-001-HOUSE_OVERSIGHT_028413.txt p.1 View source release ↗
…1"},{"range":{"length":109,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"Celgene, then a little-known New Jersey company that had never sold a drug, ultimately took up the challenge.","type":"text"},{"ad...
Text 001 House Oversight 028413 TEXT-001-HOUSE_OVERSIGHT_028413.txt p.1 View source release ↗
…,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"When Mr. Hugin arrived at Celgene in June 1999, the company was struggling to figure out how to turn a profit on its only marketed drug, Thalomid, which had...
Text 001 House Oversight 028413 TEXT-001-HOUSE_OVERSIGHT_028413.txt p.1 View source release ↗
additions":[{"URL":"https://www.nytimes.com/2017/07/25/health/celgene-to-pay-280-million-to-settle-fraud-suit-over-cancer-drugs.html?partner=applenews&ad-keywords=APPLEMOBILE&region=written_through&asset_id=100000006090758","range":{"length...
Text 001 House Oversight 028413 TEXT-001-HOUSE_OVERSIGHT_028413.txt p.1 View source release ↗
…to Revlimid, a best-selling cancer drug that, with annual sales of $8.2 billion, made up nearly two-thirds of Celgene’s net sales in 2017.","type":"text"},{"additions":[{"URL":"https://youtu.be/K4AqlkLfs5w","range":{"length":34,"start":174}...
Text 001 House Oversight 028413 TEXT-001-HOUSE_OVERSIGHT_028413.txt p.1 View source release ↗
…t-caption","role":"caption","text":"Bob Hugin spoke in 2014 at a groundbreaking ceremony in Summit, N.J., for Celgene, the pharmaceutical company he led until stepping down to run for United States Senate. To his right are Representative Le...
Text 001 House Oversight 028413 TEXT-001-HOUSE_OVERSIGHT_028413.txt p.1 View source release ↗

Also named alongside

Want context across all of these passages at once?

Ask the documents about Celgene